Health
Melanoma Vaccine: NEJM Reports 82% Recurrence-Free at 2 Years
The peer-reviewed report adds detail to a promising trial, but the personalized vaccine remains investigational and overall-survival data are immature.
shahzad · · 7 min read
1 result for "intismeran"
The peer-reviewed report adds detail to a promising trial, but the personalized vaccine remains investigational and overall-survival data are immature.
shahzad · · 7 min read